Navigation Links
Results of the AIDA STEMI MRI sub-study presented at TCT 2012
Date:10/25/2012

MIAMI, FL OCTOBER 25, 2012 A study confirmed no differences in various measures of heart damage, according to cardiac magnetic resonance (MRI) imaging, in patients receiving the anti-clotting medication abxicimab directly into the heart (intracoronary) compared to those receiving it intravenously (IV). The results of the AIDA STEMI MRI sub-study were presented today the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation, TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.

The AIDA STEMI trial was a randomized, open-label, multicenter trial in 2,065 patients presenting with ST-elevation myocardial infarction (STEMI) comparing intracoronary (IC) versus intravenous (IV) abciximab during PCI with subsequent 12 hour intravenous infusion. Last year, researchers reported that the trial found that both methods yielded similar 90-day rates of all-cause mortality, recurrent heart attack or congestive heart failure.

Researchers enrolled 703 patients within the overall trial in a cardiac magnetic resonance imaging sub-study, one of the largest MRI sub-studies conducted in patients with STEMI. Cardiac MRI allows for a more sensitive investigation of the mechanistic and pathophysiological effects of STEMI therapies on myocardial damage and reperfusion injury.

Cardiac MRI was completed within four days after heart attack using a standardized protocol including edema imaging and late gadolinium enhancement. Researchers examined infarct size, myocardial salvage, microvascular obstruction and ventricular function to determine the potential benefits of intracoronary compared to intravenous application of abciximab.

The amount of myocardium at risk and final infarct size did not differ significantly between the IC versus the IV abciximab groups. Consequently, the myocardial salvage index was similar between the two groups. In further detailed analysis there were no differences in microvascular obstruction between both treatment groups.

"Results of this sub-study demonstrate that intracoronary as compared to intravenous abciximab did not result in a difference in myocardial damage or reperfusion injury," said lead investigator Holger Thiele, MD. Dr. Thiele is Co-Director of the University of Leipzig - Heart Center in Germany.

"These findings confirm similarities in the combined endpoint of death, reinfarction and congestive heart failure found between the two methods in the AIDA STEMI trial," Dr. Thiele said.

Dr. Thiele will present the AIDA STEMI MRI sub-study on Thursday October 25 at 12:30 PM EST in the Main Arena (Hall D) at the Miami Beach Convention Center.


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Results of the PC trial presented at TCT 2012
2. Results of the POSEIDON trial presented at TCT 2012
3. 1-year results of ADAPT-DES presented at TCT 2012
4. Comparison of Obesity Surgeries Turns Up Surprising Results
5. Results from study of Mead Johnsons Enfamil® Human Milk Fortifier Acidified Liquid published in Pediatrics
6. Missed Diagnoses in ICU Often Have Deadly Results: Review
7. Anti-clotting drugs yield similar results
8. Late-Night Cramming May Hurt School Test Results
9. New survey: Women want to SEE breast reconstruction results before cancer surgery
10. Weight-loss surgery results in positive changes in social life, medical conditions
11. Many Test Results Left Unread as Patients Leave Hospital: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... There are many ways to cook a hot ... suggests that Americans prefer their dogs straight off the grill. Of the 90 percent ... favorite way to cook a hot dog, far outpacing other cooking methods such as ...
(Date:5/26/2016)... ... , ... Connor Sports, through its Connor Cares initiative, will continue ... Catchings Legacy Tour that will commemorate the Indiana Fever legend’s hall-of-fame career and ... forms and levels of the game, Connor Sports has committed to a significantly increased ...
(Date:5/26/2016)... ... ... MadgeTech will be showcasing its line of data logging products , ... MadgeTech headquarters. With products sold in more than 100 countries around the world, MadgeTech ... , In 2012, NASA strategically set up 17 RHTemp101A MadgeTech data loggers around ...
(Date:5/26/2016)... ... May 26, 2016 , ... Memorial Day Weekend marks the ... Insurance is sharing tips to make sure your family and vehicle are ready ... Safety Council, there may be 439 deaths and an additional 50,500 serious injuries from ...
(Date:5/26/2016)... Rafael, CA (PRWEB) , ... May 26, 2016 ... ... will be offering campers a multitude of activities from daily practices, arts & ... self-confidence. , Camp Directors Amber East-D’Anna and Christy Evans have combined backgrounds in ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... India , May 27, 2016 ... the instances of hypertension is driving ambulatory blood pressure ... lose their elasticity and their ability to respond to ... pressure. This condition can lead to various cardiovascular disorders ... peripheral vascular disease. These diseases are growing in prevalence ...
(Date:5/26/2016)... New York , May 26, 2016 ... Market Research "Medical Waste Management Market - U.S. Industry Analysis, ... medical waste management market in the U.S. was valued at ... at a CAGR of 3.4% from 2015 to 2023 to ... provides exhaustive analysis of current and emerging needle free drug ...
(Date:5/25/2016)... FDA 510(k) clearance covers ... for urological and surgical applications Mauna ... Cellvizio®, the multidisciplinary confocal laser endomicroscopy (CLE) platform, ... US with the 12 th 510(k) clearance ... This new FDA clearance covers Confocal Miniprobes indicated ...
Breaking Medicine Technology: